Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.48 |
| ▸ | CA12 | O43570 | 5/20 | 0.48 |
| ▸ | CA9 | Q16790 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 5/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | AKT2 | P31751 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 2/20 | 0.39 |
| ▸ | BRAF | P15056 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5264860 | 0.89 | AKT1 (0.52) | CA2CA12CA9CA1AKT1 | |
| SCHEMBL5265600 | 0.87 | CA12 (0.41) | CA2CA12CA9HSD17B10CA1 | |
| SCHEMBL5263893 | 0.85 | ALDH1A1 (0.40) | CA2CA12CA9CA1ALDH1A1 | |
| SCHEMBL5265685 | 0.82 | AKT1 (0.41) | AKT1AKT2RAF1BRAFMMP1 | |
| SCHEMBL5265682 | 0.81 | AKT1 (0.43) | AKT1AKT2MAPTKDM4EALDH1A1 | |
| SCHEMBL5262619 | 0.80 | AKT1 (0.44) | HSD17B10AKT1AKT2MMP2KDM4E | |
| SCHEMBL5263100 | 0.78 | AKT1 (0.45) | AKT1AKT2KDM4EALDH1A1GAA | |
| SCHEMBL5262073 | 0.77 | AKT1 (0.48) | HSD17B10AKT1AKT2MAPTKDM4E | |
| SCHEMBL5264876 | 0.77 | AKT1 (0.51) | HSD17B10AKT1AKT2MAPTKDM4E | |
| SCHEMBL5262166 | 0.77 | APP (0.45) | AKT1AKT2MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660500-B1 | SUBSTITUTED IMIDAZOPYRIMIDINES FOR THE PREVENTION AND TREATMENT OF CANCER | S A L V A T LAB SA (ES) | 2007-12-12 | — | — | EP | disclosed |
| US-20060189631-A1 | Substituted imidazopyrimidines for the prevention and treatment of cancer | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189631-A1 | Substituted imidazopyrimidines for the prevention and treatment of cancer | BRCA1, CCNA1, DPYD | CA2 4031/4885CA12 4293/4885CA9 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.